The financing will be used to mature the company’s product pipeline of antibody therapeutics, particularly within the field of oncology.
Kirsten Drejer, CEO of Symphogen, said: “The current funding will support the advancement of our lead oncology program, Sym004, towards early clinical studies as Symphogen continues to build a competitive oncology franchise.
“Coinciding with our strategic decision to focus our internal R&D resources on further maturing our oncology pipeline, Symphogen also plans to broaden its external collaborative activities by engaging in partnership discussions for its anti-RSV and anti-RhD recombinant polyclonal antibody programs.”